April 25, 2008 –
Astellas Pharma, Inc. and
CoMentis, Inc. announced today that the companies have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from CoMentis’ beta-secretase inhibitor program, including CoMentis’ lead candidate compound CTS-21166, an orally bioavailable, small-molecule beta-secretase inhibitor which is being developed as a disease-modifying treatment for Alzheimer’s disease.
The agreement also includes a research collaboration to develop additional beta-secretase inhibitors...
CoMentis' Press Release -
[PDF] Astellas Pharma's Press Release -
